3 Under-the-Radar Stocks to Buy and Hold

Biotech coverage highlights strong momentum across three names: Axsome Therapeutics Q1 revenue +57% YoY to $191.2M, aided by an Auvelity label expansion for Alzheimer’s agitation; Exelixis Q1 revenue +10% YoY to $610.8M, with growth supported as new products progress toward approval; and Madrigal Pharmaceuticals projects Rezdiffra could exceed $1B in annual sales this year. The article frames near- to mid-term upside from new launches/indication expansions and late-stage pipelines, with no explicit near-term downside catalysts mentioned.

Analysis

This is less a sector call than a quality-filtered revenue-duration trade. The market usually rewards biotechs when they move from binary pipeline optionality to repeatable commercial cash flow, and that transition can re-rate EV/sales multiples faster than the underlying earnings line if adoption is durable. The key question for AXSM and EXEL is not whether growth exists, but whether the market begins to underwrite a longer self-funded runway that reduces future dilution and buyout dependence.

AXSM has the cleanest near-term mechanism: a label-driven demand inflection can translate into better sales-force leverage and faster payer normalization, which matters more than TAM rhetoric over the next 1-3 quarters. EXEL is the stronger second-order story: if the next readout/approval de-risks the post-2030 franchise, the stock can migrate from a "cash cow with a cliff" discount to a platform valuation, and that multiple change can happen before meaningful revenue contribution from the new asset. The main risk is clinical/regulatory slippage or a safety profile that limits line-of-therapy penetration.

MDGL is more fragile despite good commercial momentum because one-product concentration makes the stock highly sensitive to any slowdown in specialist conversion or competitive data from larger metabolic-liver players over the next 6-18 months. Consensus likely underestimates how quickly MASH can become crowded once better-capitalized entrants arrive; the stock can look expensive on a single-asset lens if market share gains decelerate even modestly. The contrarian view is that the article may overstate medium-term certainty: these names are not all the same, and the spread between "real franchise" and "one-asset story" should widen as the next catalyst cycle unfolds.

Key Decisions for Investors

• Long AXSM on pullbacks; use a 1-3 month horizon to fade weakness if Auvelity/label-expansion adoption continues to translate into sequential revenue acceleration. Falsifier: any guidance reset or evidence of payer friction that slows script growth.
• Long EXEL into the next 6-12 months as a de-risking trade on zanzalintinib; this is a "protect the downside cliff" setup with upside if the market starts valuing post-2030 cash flows. Falsifier: delayed approval, weaker efficacy/safety readout, or signs of premature peak-sales discounting.
• Relative value: long AXSM / short XBI to isolate company-specific execution from broader biotech multiple compression. Best entry is on a sector pullback; thesis breaks if AXSM stops outperforming on revenue revisions.
• Use MDGL as a tactical relative short against AXSM or EXEL if you expect MASH competition risk to re-enter the tape over the next 3-6 months. Falsifier: sustained specialist penetration above current trend or a materially higher-than-expected addressable patient conversion rate.
• Avoid paying full momentum multiples for all three at once; prefer staged entries after catalysts rather than ahead of them, since the market already likes the narrative and the main upside is in confirming adoption, not in the press-release headline itself.